{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-058698","form_type":"8-K","ticker":null,"cik":"0000727207","company_name":"Accelerate Diagnostics, Inc","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.833579+00:00","generated_at":"2026-06-02T14:37:42.353318+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Accelerate Diagnostics reports preliminary Q1 net loss of $17.0M; Wave trial on track","bullets":["Q1 net sales $2.9M (+4% YoY); gross margin 25% vs 36% due to lower capital instrument mix.","Net loss $17.0M ($0.88 per share); cash used $9.0M net of financing, including ~$1M prepaid annual expenses.","Pre-clinical trial site installed for Accelerate Wave system; Gram Positive PBC menu development begun.","Contracts secured covering ~70% of U.S. Pheno base; 12 new Pheno instruments added; 348 revenue-generating instruments at quarter-end.","SG&A fell to $5.7M from $10.1M; R&D to $5.2M from $7.0M; both reflect lower employee costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-058698","json":"https://secwatch.observer/filing/0001104659-24-058698.json","markdown":"https://secwatch.observer/filing/0001104659-24-058698.md","text":"https://secwatch.observer/filing/0001104659-24-058698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/727207/000110465924058698/0001104659-24-058698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/727207/000110465924058698/tm2413892d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T14:37:42.353318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8817bac7101796a7b27e995e937973ad9b4845b2","claim":"Accelerate Diagnostics, Inc reported first quarter ended March 31, 2024 results: revenue $2.9 million, net income Net loss was $17.0 million, EPS $0.88 net loss per share.","evidence_excerpt":"and another 75 contracted instruments in the process of being implemented. First Quarter 2024 Preliminary Financial Highlights § Net sales for the quarter were $2.9 million, compared to $2.8 million for the same quarter of the prior year. Revenues from consumable products increased by 7% compared to the same period in the prior year. § Gross margin","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/727207/000110465924058698/0001104659-24-058698-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$2.9 million"},{"label":"Net income","value":"Net loss was $17.0 million"},{"label":"EPS","value":"$0.88 net loss per share"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}